Overview

• The 72‑week, international phase 3 trial followed 3,100 adults with obesity but without diabetes, with results published in The New England Journal of Medicine and presented at EASD in Vienna.
• At the highest dose, participants lost a mean 11.2% of body weight, with over half achieving at least 10% loss and about 18% exceeding 20%.
• Secondary outcomes showed improvements in blood pressure, waist circumference, triglycerides and cholesterol, aligning with reduced cardiometabolic risk.
• Adverse events were mainly gastrointestinal and generally mild to moderate and self‑limited, consistent with the GLP‑1 drug class.
• Developed by Eli Lilly with participation from Hospital Vall d'Hebron, the drug is intended for obesity treatment only, and the lead investigator says FDA approval could come in early 2026.